Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells.

Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells, for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia.

Gamida Cells flagship product, StemEx^®, is currently being studied as a treatment for hematological malignancies or blood cancers including leukemia and lymphoma in an open, global, pivotal Phase II/III, registration study called ExCell, now recruiting patients at prestigious cord blood transplant centers in the US, Europe and Israel. For more information regarding ExCell, please visit www.stemexstudy.com

The market launch of StemEx is planned for 2011.